Burcu Çalışkan (Burcu Caliskan)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Molecular Docking

Positive Breast Cancer

Glycemic Control

Top Venues

Cancer research

Archiv der Pharmazie

This page only lists publications with an associated author ORCID identifier.

Publications

Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer research (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer. Cancer research 84 (9) (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer research (2024)
Mustafa Emre Gedik, Ozge Saatci, Nathaniel Oberholtzer, Meral Uner, Ozge Akbulut-Caliskan, Metin Cetin, Mertkaya Aras, Kubra Ibis, Burcu Çalışkan, Erden Banoglu, Stefan Wiemann, Aysegül Uner, Sercan Aksoy, Shikhar Mehrotra, Özgür Sahin
Targeting TACC3 induces immunogenic cell death and enhances T-DM1 response in HER2-positive breast cancer. Cancer research (2024)
Tuğçe Gür Maz, Beyzanur Koc, Paul M Jordan, Kubra Ibis, Burcu Çalışkan, Oliver Werz, Erden Banoglu
Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors. ACS omega 8 (2) (2023)
Tuğçe Gür Maz, Beyzanur Koc, Paul M Jordan, Kubra Ibis, Burcu Çalışkan, Oliver Werz, Erden Banoglu
Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors. ACS omega 8 (2) (2023)
Sümeyye Turanlı, Esra Nalbat, Deniz Lengerli, Kubra Ibis, Sezen Güntekin Ergün, Ece Akhan Güzelcan, Mesut Muyan, Rengul Cetin-Atalay, Burcu Çalışkan, Erden Banoglu
Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity. ACS omega 7 (41) (2022)
Sümeyye Turanlı, Azize Gizem Ergül, Paul M Jordan, Abdurrahman Olğaç, Burcu Çalışkan, Oliver Werz, Erden Banoglu
Quinazoline-4(3 H )-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition. ACS omega 7 (41) (2022)
Tuğçe Gür Maz, Sumeyye Turanlı, Huseyin Burak Caliskan, Burcu Çalışkan, Erden Banoglu
Development and molecular modeling studies of new thiadiazole piperazine urea derivatives as potential fatty acid amide hydrolase inhibitors. Archiv der Pharmazie 355 (8) (2022)